Literature DB >> 29623835

ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease.

Wei Chen1, Fengzhong Jin1, Guihua Cao1, Rong Mei2, Yayun Wang3, Pan Long4, Xiaoming Wang1, Wei Ge1.   

Abstract

Alzheimer disease (AD) is most common neurodegenerative disorder of dementia, as we all know that ApoE4 is the greatest genetic risk factor of late-onset Alzheimer's disease (LOAD). Coronary heart disease (CHD) leads to one-fourth of all deaths in industrialized countries, it is reported that ApoE4 increases the risk of coronary heart disease as well. Furthermore, evidence show that coronary heart disease also increases the incidence of Alzheimer's disease. Whether ApoE4 is a bridge connecting AD with CHD or not? And what are the special mechanism and therapeutic methods? Researchers found that cholesterol metabolic disorder is the common cause and risk factor of AD and CHD. Epidemiological studies demonstrate that carriers of the ApoE4 allele have higher cholesterol plasma concentration. More evidence indicate that hypercholesterolemia accelerates the progression of coronary atherosclerosis, damages the central nervous system blood-brain barrier, promotes Aβ protein production and Tau deposition in brain. Therefore, ApoE4 is likely to be the bridge between AD and CHD, and may be a potentially promising therapeutic target. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's disease (AD); ApoE4; cardiovascular disease; central nervous system; coronary heart disease (CHD); hypercholesterolemia.

Mesh:

Substances:

Year:  2018        PMID: 29623835     DOI: 10.2174/1389450119666180406112050

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  7 in total

1.  Correlations Between Single Nucleotide Polymorphisms, Cognitive Dysfunction, and Postmortem Brain Pathology in Alzheimer's Disease Among Han Chinese.

Authors:  Qian Yang; Kang Chen; Hanlin Zhang; Wanying Zhang; Changlin Gong; Qing Zhang; Pan Liu; Tianyi Sun; Yuanyuan Xu; Xiaojing Qian; Wenying Qiu; Chao Ma
Journal:  Neurosci Bull       Date:  2019-02-19       Impact factor: 5.203

2.  The relationship between ApoE gene polymorphism and the efficacy of statins controlling hyperlipidemia.

Authors:  Cong Cai; Zhongzheng Wen; Linrui Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  The risk of dementia after coronary artery bypass grafting in relation to age and sex.

Authors:  Kok Wai Giang; Anders Jeppsson; Martin Karlsson; Emma C Hansson; Aldina Pivodic; Ingmar Skoog; Martin Lindgren; Susanne J Nielsen
Journal:  Alzheimers Dement       Date:  2021-03-04       Impact factor: 21.566

4.  Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population.

Authors:  Yuxia Li; Meimei Kang; Can Sheng; Guanqun Chen; Taoran Li; Jun Wang; Yanning Cai; Rong Wang; Ying Han
Journal:  Neural Plast       Date:  2020-06-06       Impact factor: 3.599

Review 5.  The Emerging Role of Metabolism in Brain-Heart Axis: New Challenge for the Therapy and Prevention of Alzheimer Disease. May Thioredoxin Interacting Protein (TXNIP) Play a Role?

Authors:  Lorena Perrone; Mariarosaria Valente
Journal:  Biomolecules       Date:  2021-11-08

6.  Risk factors for dementia in the context of cardiovascular disease: A protocol of an overview of reviews.

Authors:  Jacob Brain; Phillip J Tully; Deborah Turnbull; Eugene Tang; Leanne Greene; Sarah Beach; Mario Siervo; Blossom C M Stephan
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

7.  Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response.

Authors:  Baoyu Yuan; Xiaoyan Sun; Zhi Xu; Mengjia Pu; Yonggui Yuan; Zhijun Zhang
Journal:  BMC Psychiatry       Date:  2020-08-14       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.